Publications by authors named "T Senoh"
Article Synopsis
- The study aimed to evaluate the effectiveness and tolerability of direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) across different genotypes (GTs) in a global, real-world context, focusing particularly on GT3 and GT6.
- Researchers analyzed data from 15,849 chronic hepatitis C patients across Asia, North America, and Europe over a seven-year period, noting demographic factors such as age, sex, and prior treatment history.
- Results showed a high sustained virological response (SVR12) rate of 96.9% overall, with variances by genotype, highlighting that independent factors like advanced age, cirrhosis, and previous treatment failures affected treatment outcomes, while being
Article Synopsis
- The study investigates how esophageal varices change in patients with cirrhosis after achieving sustained virological response (SVR) using direct-acting antivirals (DAAs).
- 243 patients were examined before and after DAA treatment, revealing that 14.8% experienced worsened varices post-SVR and 11.9% showed improvement.
- The ALBI score at SVR12 was identified as a significant predictor for both worsening varices and the development of new varices, with specific cut-off values highlighting the risk.
- Despite achieving SVR, patients with high ALBI scores remain at risk for negative changes in their esophageal varices.
Aim: An association between hepatitis B core-related antigen (HBcrAg) kinetics and hepatocarcinogenesis during nucleoside (t)id analog (NA) treatment has recently been reported. HBcrAg kinetics and factors associated with HBcrAg response during tenofovir alafenamide (TAF) administration remain unclear. In this multicenter retrospective study, we aimed to clarify the efficacy and safety of TAF in treatment-naïve patients with chronic hepatitis B, focusing on the reduction in HBcrAg levels.
View Article and Find Full Text PDFBackground And Aim: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear.
Methods: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort.
Article Synopsis
- - Elevated serum gamma-glutamyl transferase (GGT) levels are linked to higher mortality rates in chronic hepatitis B (CHB) patients receiving nucleotide/nucleoside analog treatments, showing significant increases in GGT measurements before and six months after treatment.
- - A study analyzing 2,843 CHB patients found that factors such as cirrhosis, age, and pretreatment GGT levels are strong predictors of both all-cause and liver-related mortality, with cirrhosis having the highest hazard ratio.
- - The link between pretreatment GGT levels and mortality remains consistent regardless of alcohol use history, and there is a noticeable dose-dependent association with different percentiles of GGT indicating increased mortality risk